CA1087966A - Process and a metachromatic composition for effecting a count of leucocytes, and more particularly of basophiles - Google Patents
Process and a metachromatic composition for effecting a count of leucocytes, and more particularly of basophilesInfo
- Publication number
- CA1087966A CA1087966A CA255,681A CA255681A CA1087966A CA 1087966 A CA1087966 A CA 1087966A CA 255681 A CA255681 A CA 255681A CA 1087966 A CA1087966 A CA 1087966A
- Authority
- CA
- Canada
- Prior art keywords
- blood
- basophils
- composition
- sample
- allergen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000003651 basophil Anatomy 0.000 title claims abstract description 127
- 238000000034 method Methods 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 230000008569 process Effects 0.000 title claims abstract description 25
- 230000003458 metachromatic effect Effects 0.000 title claims description 9
- 210000004369 blood Anatomy 0.000 claims abstract description 150
- 239000008280 blood Substances 0.000 claims abstract description 150
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 230000035945 sensitivity Effects 0.000 claims abstract description 20
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 17
- 230000007815 allergy Effects 0.000 claims abstract description 16
- 230000002052 anaphylactic effect Effects 0.000 claims abstract description 11
- 239000000834 fixative Substances 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims description 81
- 102000036639 antigens Human genes 0.000 claims description 81
- 108091007433 antigens Proteins 0.000 claims description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 45
- 239000000470 constituent Substances 0.000 claims description 32
- 239000013566 allergen Substances 0.000 claims description 31
- 239000011575 calcium Substances 0.000 claims description 27
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 26
- 229910052791 calcium Inorganic materials 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 229960000583 acetic acid Drugs 0.000 claims description 17
- 229950003937 tolonium Drugs 0.000 claims description 16
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical group [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 15
- 210000003743 erythrocyte Anatomy 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 14
- 238000011534 incubation Methods 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 239000012362 glacial acetic acid Substances 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 230000002101 lytic effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000009920 chelation Effects 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims 15
- HKLYDUXIXBVZOQ-UHFFFAOYSA-N 2-aminoethane-1,1,1-triol Chemical compound NCC(O)(O)O HKLYDUXIXBVZOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000012445 acidic reagent Substances 0.000 claims 1
- 238000007864 suspending Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 61
- 238000000338 in vitro Methods 0.000 abstract description 9
- 239000000523 sample Substances 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 18
- 238000012505 colouration Methods 0.000 description 17
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 238000004040 coloring Methods 0.000 description 14
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
- 229920000669 heparin Polymers 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000013019 agitation Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 230000003112 degranulating effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000006740 morphological transformation Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 150000004992 toluidines Chemical class 0.000 description 2
- KHJWSKNOMFJTDN-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KHJWSKNOMFJTDN-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000497851 Anaphes Species 0.000 description 1
- 241001502381 Budorcas taxicolor Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000533867 Fordia Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 101000894412 Mycolicibacterium paratuberculosis (strain ATCC BAA-968 / K-10) Bacterioferritin Proteins 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical group CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical compound CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/305—Fixative compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physiology (AREA)
- Ecology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7520273 | 1975-06-27 | ||
| FR7520273A FR2315251A1 (fr) | 1975-06-27 | 1975-06-27 | Procede et composition metachromatique pour la numeration des leucocytes, plus particulierement des basophiles |
| FR7609146A FR2346717A2 (fr) | 1976-03-30 | 1976-03-30 | Procede et composition metachromatique pour la numeration des leucocytes, plus particulierement des basophiles |
| FR7609146 | 1976-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1087966A true CA1087966A (en) | 1980-10-21 |
Family
ID=26218951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA255,681A Expired CA1087966A (en) | 1975-06-27 | 1976-06-25 | Process and a metachromatic composition for effecting a count of leucocytes, and more particularly of basophiles |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5819063B2 (xx) |
| CA (1) | CA1087966A (xx) |
| CH (1) | CH613523A5 (xx) |
| DE (1) | DE2628468C2 (xx) |
| DK (1) | DK289076A (xx) |
| GB (1) | GB1560729A (xx) |
| NL (1) | NL171840C (xx) |
| SE (1) | SE437079B (xx) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4640897A (en) * | 1979-06-28 | 1987-02-03 | Institut Pasteur | Immunoanalysis of basophil-containing blood fraction for diagnosing parasitoses and allergies |
| WO1988007187A1 (en) * | 1987-03-13 | 1988-09-22 | Coulter Electronics, Inc. | System for isolating and identifying leukocytes |
| US5155044A (en) * | 1987-03-13 | 1992-10-13 | Coulter Electronics, Inc. | Lysing reagent system for isolation, identification and/or analysis of leukocytes from whole blood samples |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321251A (en) * | 1979-12-19 | 1982-03-23 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse |
| US4840784A (en) * | 1982-12-22 | 1989-06-20 | Eastman Kodak Company | Use of pyrylium and thiapyrylium compounds as biological stains |
| US4555396A (en) * | 1982-12-22 | 1985-11-26 | Eastman Kodak Company | Use of pyrylium and thiapyrylium compounds as biological stains |
| SE461660B (sv) * | 1983-04-19 | 1990-03-12 | Bio Instructa Labkonsult | Foerfarande foer analys av receptorers aktivitet hos celler |
| HU186309B (en) * | 1983-09-02 | 1985-07-29 | Reanal Finomvegyszergyar | Reagent for determining the thrombacyta and leucocyte number |
| EP0177352A1 (en) * | 1984-10-04 | 1986-04-09 | The State Of Victoria | Improvements in or relating to enzyme-linked immunosorbent assay |
| JPS62135752U (xx) * | 1986-02-20 | 1987-08-26 | ||
| JPH0448708Y2 (xx) * | 1986-04-10 | 1992-11-17 | ||
| CA1309327C (en) * | 1986-09-10 | 1992-10-27 | Tomoyuki Kuroda | Reagent and method for classifying leukocytes by flow cytometry |
| US5039613A (en) * | 1986-11-27 | 1991-08-13 | Toa Medical Electronics Co., Ltd. | Reagents used in a method of classifying leukocytes by flow cytometry |
| US5179026A (en) * | 1986-11-27 | 1993-01-12 | Toa Medical Electronics Co., Ltd. | Method of classifying leukocytes by flow cytometry and reagents used in the method |
| PT106082A (pt) * | 2012-01-04 | 2013-07-04 | Fernando Jorge Neves Ferreira | Composição fixadora para citologia, método de fixação de células e suas aplicações |
| EP4267934A1 (en) * | 2020-12-22 | 2023-11-01 | Radiometer Medical ApS | Method for monitoring and adjusting reagent for hematology |
-
1976
- 1976-06-21 CH CH787076A patent/CH613523A5/xx not_active IP Right Cessation
- 1976-06-24 SE SE7607282A patent/SE437079B/xx not_active IP Right Cessation
- 1976-06-25 DK DK289076A patent/DK289076A/da not_active Application Discontinuation
- 1976-06-25 DE DE19762628468 patent/DE2628468C2/de not_active Expired
- 1976-06-25 NL NL7607012A patent/NL171840C/xx not_active IP Right Cessation
- 1976-06-25 CA CA255,681A patent/CA1087966A/en not_active Expired
- 1976-06-28 GB GB2676876A patent/GB1560729A/en not_active Expired
- 1976-06-28 JP JP51076303A patent/JPS5819063B2/ja not_active Expired
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4640897A (en) * | 1979-06-28 | 1987-02-03 | Institut Pasteur | Immunoanalysis of basophil-containing blood fraction for diagnosing parasitoses and allergies |
| WO1988007187A1 (en) * | 1987-03-13 | 1988-09-22 | Coulter Electronics, Inc. | System for isolating and identifying leukocytes |
| US5155044A (en) * | 1987-03-13 | 1992-10-13 | Coulter Electronics, Inc. | Lysing reagent system for isolation, identification and/or analysis of leukocytes from whole blood samples |
| US5731206A (en) * | 1987-03-13 | 1998-03-24 | Coulter Electronics, Inc. | Method and reagent system for isolation, identification and/or analysis of leukocytes from whole blood samples |
Also Published As
| Publication number | Publication date |
|---|---|
| DK289076A (da) | 1976-12-28 |
| JPS5224589A (en) | 1977-02-24 |
| GB1560729A (en) | 1980-02-06 |
| CH613523A5 (en) | 1979-09-28 |
| NL171840C (nl) | 1983-05-16 |
| SE7607282L (sv) | 1976-12-28 |
| NL171840B (nl) | 1982-12-16 |
| DE2628468C2 (de) | 1982-05-06 |
| JPS5819063B2 (ja) | 1983-04-15 |
| DE2628468A1 (de) | 1976-12-30 |
| NL7607012A (nl) | 1976-12-29 |
| SE437079B (sv) | 1985-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1087966A (en) | Process and a metachromatic composition for effecting a count of leucocytes, and more particularly of basophiles | |
| Beutler et al. | The hemolytic effect of primaquine: VI. An in vitro test for sensitivity of erythrocytes to primaquine | |
| Duggan et al. | Sarcoplasmic reticulum: IX. The permeability of sarcoplasmic reticulum membranes | |
| Dodge et al. | The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes | |
| Key | Studies on erythrocytes, with special reference to reticulum, polychromatophilia and mitochondria | |
| US3915805A (en) | Quantitative detection of endotoxin in biological fluids | |
| Larcom et al. | Erythrocytes in urinary sediment: Identification and normal limits: With a note on the nature of granular casts | |
| CN106018852B (zh) | 用于分析试验的个体化质量对照物 | |
| Feinberg et al. | Diagnostic tests for choreoacanthocytosis | |
| Louw et al. | Kinetics of erythrocyte lysis by snake venom cardiotoxins | |
| Walter et al. | Factors in the partition of red blood cells in aqueous dextran-polyethylene glycol two-phase systems | |
| US4640897A (en) | Immunoanalysis of basophil-containing blood fraction for diagnosing parasitoses and allergies | |
| JP4105768B2 (ja) | タンパク質の抽出方法 | |
| Booyse et al. | Studies on Human Platelets | |
| JPH0630633B2 (ja) | アレルギーの検出法並びに該方法に好適な試薬及び装置、及びアレルギー用薬及び抗炎症剤の測定法 | |
| US4020006A (en) | Fluid containing dispersed particles simulating leukocytes and method for producing same | |
| US3961039A (en) | Urinary sediment stain | |
| Harris | The osmotic properties of cytoplasmic granules of the sea urchin egg | |
| Andersen | Modifying Influence of the Secretor Gene on the Development of the ABH Substance* A Contribution to the Conception of the Lewis Group System | |
| US3918905A (en) | Diagnostic test for the determination of sickling hemoglobinopathies | |
| Fazekas et al. | A competitive protein binding assay for urinary riboflavin | |
| Brammer et al. | Vervet monkey (Cercopithecus aethiops sabaeus) whole blood serotonin level is determined by platelet uptake sites | |
| Crespo et al. | Calcium, cell shrinkage, and prolytic state of human red blood cells | |
| Samuels et al. | Chemical and ultrastructural comparison of synthetic and pathologic membrane system | |
| IE44194B1 (en) | Improvements in or relating to the counting of leucocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |